Based on the results of the submitted ITC oral semaglutide both as second- and third-line therapy is likely better than placebo and the results suggest potential superiority to other treatment classes, specifically SGLT-2, DPP-4 inhibitors, TZD, and SUs
The results showed that the mens average A1C levels decreased from 7.87% to 5.99% (for reference, normal A1C levels are 5.7% or lower and people with 6.5% or higher are considered diabetic)
[Abstract] Kaohsiung J Med Sci
It is also important to note that semaglutide is a medication that has potential side effects and is not suitable for everyone
The company reports earnings on Monday, and investors are looking for signs of revenue growth after the numbers in its last report showed deceleration
Understanding how it stacks up against other popular options can help you determine whether it is the right fit for your goals